Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXVIQN)

Drug Name

MOR-103 Drug Info

Synonyms

MOR-04357; Antibody (inflammation), MorphoSys; GM-CSF antibody (rheumatoid arthritis), MorphoSys; MOR-103 (rheumatoid arthritis), MorphoSys; GM-CSF antibody (iv infusion, inflammation), MorphoSys/Galapagos

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 1/2	[1]

Cross-matching ID

TTD Drug ID: DMXVIQN

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting GMCSFR-alpha (CSF2RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sargramostim	DMY0M8J	Bone marrow transplantation	QB63.6	Approved	[3]
B-cell lymphoma vaccine	DMBRFUQ	Follicular lymphoma	2A80	Preregistration	[4]
Pixykine	DMCA6BW	Human immunodeficiency virus infection	1C62	Phase 3	[5]
Molgramostim	DM2TNJ1	Autoimmune pulmonary alveolar proteinosis	CB04.31	Phase 3	[6]
AFTVac	DMD3XMG	Glioblastoma multiforme	2A00.0	Phase 2	[7]
Mavrilimumab	DMMVFRC	Rheumatoid arthritis	FA20	Phase 2	[8]
GM-CSF cancer vaccine	DML6PO5	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
Leukemia cancer vaccine	DMIFGLY	Acute myeloid leukaemia	2A60	Phase 2	[9]
Myeloma cancer vaccine	DMO1XUK	Multiple myeloma	2A83	Phase 2	[9]
KH-901	DMR14VE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GMCSFR-alpha (CSF2RA)	TT6MP2Z	CSF2R_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01023256) Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis. U.S. National Institutes of Health.
2	MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64.
3	Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9.
4	Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2.
5	Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7.
6	Clinical pipeline report, company report or official report of gensci-china.
7	Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
8	Clinical pipeline report, company report or official report of MedImmune (2011).
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
10	Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):386-90.